Format

Send to

Choose Destination
Allergy. 2016 Nov;71(11):1513-1525. doi: 10.1111/all.12880. Epub 2016 Aug 23.

Paving the way of systems biology and precision medicine in allergic diseases: the MeDALL success story: Mechanisms of the Development of ALLergy; EU FP7-CP-IP; Project No: 261357; 2010-2015.

Author information

1
University Hospital, Montpellier, France. jean.bousquet@orange.fr.
2
MACVIA-LR, Contre les MAladies Chroniques pour un VIeillissement Actif en Languedoc-Roussillon, European Innovation Partnership on Active and Healthy Ageing Reference Site, France. jean.bousquet@orange.fr.
3
INSERM, VIMA: Ageing and Chronic Diseases, Epidemiological and Public Health Approaches, UVSQ, Université Versailles St-Quentin-en-Yvelines, Paris, France. jean.bousquet@orange.fr.
4
Centre for Research in Environmental Epidemiology (CREAL), ISGLoBAL, Barcelona, Spain.
5
IMIM (Hospital del Mar Research Institute), Barcelona, Spain.
6
CIBER Epidemiología y Salud Pública (CIBERESP), Barcelona, Spain.
7
Universitat Pompeu Fabra (UPF), Barcelona, Spain.
8
Swiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, Davos, Switzerland.
9
European Institute for Systems Biology and Medicine, CNRS-ENS-UCBL, Université de Lyon, Lyon, France.
10
Institute of Social Medicine, Epidemiology and Health Economics, Charité-Universitätsmedizin Berlin, Berlin, Germany.
11
Institute for Clinical Epidemiology and Biometry, University of Wuerzburg, Wuerzburg, Germany.
12
Department of Public Health and Health Products, Paris Descartes University-Sorbonne Paris Cité, Paris, France.
13
Paris Municipal Department of Social Action, Childhood, and Health, Paris, France.
14
Department of Pulmonary Medicine and Tuberculosis, GRIAC Research Institute, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.
15
Division of Immunopathology, Department of Pathophysiology and Allergy Research, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria.
16
Sachs' Children and Youth Hospital, Södersjukhuset, Stockholm and Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden.
17
UMR Inserm U1027 and Université de Toulouse III Paul Sabatier, Toulouse, France.
18
Skin and Allergy Hospital, Helsinki University Hospital, Helsinki, Finland.
19
VIB Inflammation Research Center, Ghent University, Ghent, Belgium.
20
Department of Paediatrics, Faculty of Medicine, Institute of Clinical Medicine, Oslo University Hospital, University of Oslo, Oslo, Norway.
21
Department of Pediatric Pulmonology and Pediatric Allergology, Beatrix Children's Hospital, GRIAC Research Institute, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.
22
Secretary General of the Global Allergy and Asthma European Network (GA2LEN), Allergy-Centre-Charité at the Department of Dermatology, Charité-Universitätsmedizin Berlin, Berlin, Germany.
23
EPAR U707 INSERM, EPAR UMR-S UPMC, Paris VI, Paris, France.
24
Onmedic Networks, Barcelona, Spain.
25
Department of Dermatology and Allergy Centre, Odense University Hospital, Odense, Denmark.
26
EFA European Federation of Allergy and Airways Diseases Patients' Associations, Brussels, Belgium.
27
Department of Epidemiology, Regional Health Service Lazio Region, Rome, Italy.
28
Institute of Epidemiology I, German Research Centre for Environmental Health, Helmholtz Zentrum München, Neuherberg, Germany.
29
Department of Immunology, Rheumatology and Allergy, Medical University of Lodz, Lodz, Poland.
30
Biomax Informatics AG, Munich, Germany.
31
Stockholm County Council, Centre for Occupational and Environmental Medicine, Stockholm, Sweden.
32
Julius Center of Health Sciences and Primary Care, University Medical Center Utrecht, University of Utrecht, Utrecht, the Netherlands.
33
Bradford Institute for Health Research, Bradford Royal Infirmary, Bradford, UK.
34
Clinical Immunology and Allergy Unit, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden.
35
Astrid Lindgren Children's Hospital, Department of Pediatric Pulmonology and Allergy, Karolinska University Hospital, Stockholm, Sweden.
36
St John's Institute of Dermatology, King's College London, London, UK.
37
Institute for Risk Assessment Sciences, Utrecht University, Utrecht, the Netherlands.
38
Institute of Social Medicine, Epidemiology and Health Economics, Charité-Universitätsmedizin, Berlin, Germany.
39
Department of Clinical Science and Education, Södersjukhuset, Karolinska Institutet, Stockholm, Sweden.
40
Department of Clinical Science, Intervention and Technology, Karolinska Institutet, Stockholm, Sweden.
41
Department of ENT Diseases, Karolinska University Hospital, Stockholm, Sweden.
42
Inserm Transfert, Paris, France.
43
Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden.
44
ENT Department, Ghent University Hospital, Gent, Belgium.
45
Environment and Health Area, Centre for Public Health Research (CSISP), CIBERESP, Department of Nursing, University of Valencia, Valencia, Spain.
46
MACVIA-LR, Contre les MAladies Chroniques pour un VIeillissement Actif en Languedoc-Roussillon, European Innovation Partnership on Active and Healthy Ageing Reference Site, France.
47
Research Institute, Department of Pediatrics, Marien-Hospital, Wesel, Germany.
48
INSERM, VIMA: Ageing and Chronic Diseases, Epidemiological and Public Health Approaches, UVSQ, Université Versailles St-Quentin-en-Yvelines, Paris, France.
49
Department of Paediatrics, Oslo University Hospital, University of Oslo, Oslo, Norway.
50
Department of Social Medicine, Faculty of Medicine, University of Crete, Heraklion, Crete, Greece.
51
Department of Respiratory Diseases, Montpellier University Hospital, France.
52
Department of Medicine and Public Health, Alma Mater Studiorum-University of Bologna, Bologna, Italy.
53
Allergology Department, Centre de l'Asthme et des Allergies, Hôpital d'Enfants Armand-Trousseau (APHP), Sorbonne Universités, Institut Pierre Louis d'Epidémiologie et de Santé Publique, Paris, France.
54
Division of Paediatric Gastroenterology and Hepatology, Ludwig Maximilians University of Munich, Munich, Germany.
55
Department for Pediatric Pneumology and Immunology, Charité Medical University, Berlin, Germany.
56
Department of Environmental Immunology/Core Facility Studies, Helmholtz Centre for Environmental Research, UFZ, Leipzig, Germany.
57
Chemotargets SL and Chemogenomics Laboratory, GRIB Unit, IMIM-Hospital del Mar and University Pompeu Fabra, Barcelona, Catalonia, Spain.
58
Département de Pédiatrie, CHU de Grenoble, Grenoble Cedex 9, France.
59
Inserm, U823, Grenoble, France.
60
ib-salut, Area de Salut de Menorca, Spain.

Abstract

MeDALL (Mechanisms of the Development of ALLergy; EU FP7-CP-IP; Project No: 261357; 2010-2015) has proposed an innovative approach to develop early indicators for the prediction, diagnosis, prevention and targets for therapy. MeDALL has linked epidemiological, clinical and basic research using a stepwise, large-scale and integrative approach: MeDALL data of precisely phenotyped children followed in 14 birth cohorts spread across Europe were combined with systems biology (omics, IgE measurement using microarrays) and environmental data. Multimorbidity in the same child is more common than expected by chance alone, suggesting that these diseases share causal mechanisms irrespective of IgE sensitization. IgE sensitization should be considered differently in monosensitized and polysensitized individuals. Allergic multimorbidities and IgE polysensitization are often associated with the persistence or severity of allergic diseases. Environmental exposures are relevant for the development of allergy-related diseases. To complement the population-based studies in children, MeDALL included mechanistic experimental animal studies and in vitro studies in humans. The integration of multimorbidities and polysensitization has resulted in a new classification framework of allergic diseases that could help to improve the understanding of genetic and epigenetic mechanisms of allergy as well as to better manage allergic diseases. Ethics and gender were considered. MeDALL has deployed translational activities within the EU agenda.

KEYWORDS:

IgE; asthma; multimorbidity; polysensitization; rhinitis

PMID:
26970340
PMCID:
PMC5248602
DOI:
10.1111/all.12880
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Wiley Icon for PubMed Central
Loading ...
Support Center